DementiaNCT06266325
Development and Validation of a Dementia Life Expectancy Tool
An observational study of Dementia and Death, run by University of Toronto.
Trial summary
Individuals with dementia and their caregivers are faced with challenging decisions throughout the course of the disease. These decisions may be about medical care (e.g., continuation of routine cancer screening, pursuit of cardiopulmonary resuscitation, initiation of palliative care services), institutionalization… Read more about this study
- Who is it for?
- Ages 65 years and older
- How many people
- 202,217 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2010to 31 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: The cohort will comprise individuals with dementia who are expected to be or currently are recipients of long-stay home care, who, after diagnosis of dementia, underwent any home care assessment from April 1st, 2010 to March 31st, 2020
Who may be able to join
- Diagnosed with dementia determined by a combination of a validated case definition and by indicators of dementia in the home care assessment
- Recipients of home care, who, after diagnosis of dementia, underwent any home care assessment from April 1st, 2010 to March 31st, 2020
Who cannot join
- Age <65 on the date of dementia diagnosis
- Invalid age or sex
- Invalid birthdate (e.g., after date of dementia diagnosis) or death date (e.g., before date of dementia diagnosis)
- Ineligibility for Ontario Health Insurance Program at the time of the home care assessment
About this study
Official title: Development and Validation of a Clinical Prediction Tool to Estimate Life Expectancy in Community-dwelling Individuals With Dementia
Individuals with dementia and their caregivers are faced with challenging decisions throughout the course of the disease. These decisions may be about medical care (e.g., continuation of routine cancer screening, pursuit of cardiopulmonary resuscitation, initiation of palliative care services), institutionalization (i.e., transition to a long-term care facility), or financial planning. These inherently difficult decisions are made more difficult by prognostic uncertainty. Indeed, life expectancy is challenging to predict in dementia. Consequently, prognosis is infrequently discussed by healthcare providers with individuals with dementia and their families, which compromises their ability to plan for the future. A lack of prognostic awareness makes it difficult for patients, their caregivers, and their healthcare providers to make medical decisions that strike the appropriate balance between prolonging life and promoting the quality of it. A clinical prediction tool has the promise to provide personalized and accurate estimations of life expectancy in individuals with dementia. Therefore, similar to the existing clinical prediction tools on our Project Big Life platform (www.projectbiglife.ca), we seek to create and to test a statistical model to predict survival, and to implement the model as a user-friendly, web-based calculator. The calculator will use self-reported sociodemographic, clinical, cognitive, functional, and nutritional information that is entered by patients, their caregivers, and/or their healthcare providers to output an estimated life expectancy. This estimate could inform the shared decision-making process, thereby empowering decisions that are compatible with a patient's clinical reality and concordant with their life goals.
Read the detailed description
Analysis plan
The analysis plan was informed by guidelines for clinical prediction modelling. The plan was developed after accessing the derivation dataset but before assessing predictor-outcome associations and model fitting. Key considerations are full pre-specification of the model, including selection of predictors, such that data-driven variable selection will be avoided. This will decrease the risk of bias and overfitting in the model. Second, continuous variables will be specified as restricted cubic splines with knots at fixed quantiles, such that categorization of continuous variables will be avoided. This will respect the non-linear nature of continuous variables, and will avoid the inefficiency and bias associated with categorization. Third, emphasis will be placed on the assessment of the model's calibration, not only in the validation cohort but also in subgroups of meaning to clinicians and policymakers. Statistical analysis will be performed using SAS Enterprise Guide V.9.4.
Validation will be performed using temporal validation, whereby the model's performance will be evaluated in a temporally distinct (more recent) cohort of individuals with dementia. This is a more rigorous form of validation compared to internal validation, which includes random splitting or resampling (bootstrapping, cross-validation). Whereas temporal validation evaluates transportability, internal validation evaluates only reproducibility. The size of the derivation cohort and the expected number of events therein enables temporal validation without significantly increasing the risk of overfitting.
Predictor variables
The candidate predictor variables were fully pre-specified, such that data-driven variable selection was avoided. The investigators reviewed variables in the home care databases to identify predictors. In addition, existing reviews of prognostic models in dementia were explored. Variables were reviewed by the research team in an itemized way to determine which to include in the initial model.
Notably, predictor values from only a single randomly selected assessment after dementia diagnosis (index assessment) will be included in the model. The investigators did not include values from subsequent assessments since the tool would be applied cross-sectionally, not longitudinally. Indeed, the team wants to avoid using values from subsequent assessments, which would not have been known at the time of the randomly selected assessment. The variables in our model will be organized in the following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information. The investigators will include interactions between age and variables that represent comorbidities since the association of these and life expectancy may vary with age. A linear term of age, not a restricted cubic spline thereof, will be used in interactions.
Outcome variable
The outcome variable will be survival time from the index assessment up to the maximum follow-up date (December 31st, 2022). Mortality will be discerned from the Registered Persons Database, which houses a historical listing of all individuals eligible for the Ontario Health Insurance Program, including sociodemographic (e.g., age, sex, postal code) and vital information (e.g., date of death). The investigators have pre-specified survival times of interest, which are compatible with current eligibility guidelines for specialist palliative care services (i.e., 3, 6, and 12 months).
Model specification
Predictor variables will be explored before assessing predictor-outcome associations or model fitting. Continuous variables will be explored using descriptive statistics and boxplots, and categorical variables using descriptive statistics and frequency distributions. Any identified invalid values will be corrected, if possible, or set to missing otherwise. Continuous variables will be specified using restricted cubic splines with knots at fixed quantiles (e.g., in a 5-knot spline, quantiles are placed at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles). Categorization of continuous variables will be avoided since this is associated with inefficiency and bias and does not respect the non-linear nature of continuous variables. Combination of levels of a categorical variable will be avoided unless a category has a very low proportion of total observations. Variables with a high degree of missing values or insufficient variation will be excluded. Multi-collinearity will be evaluated using variable clustering (VARCLUS function in SAS). The minimum proportion of variance explained by a cluster (eigenvalue) will be set to 0.7.
Missing values will be imputed using multiple imputation so long as missingness was judged to have been completely at random or at random. Despite its simplicity, complete case analysis will be avoided to prevent the inefficiency and bias associated with this method. The imputation model will include the outcome variable, predictor variables, and auxiliary variables (i.e., variables that are not included in the full model but that could inform the missing value of a variable). The number of imputed datasets will be based on the proportion of missing values in the dataset. The final model will be estimated in each of the imputed datasets. The parameter estimates based on each dataset will be combined using Rubin's rules, which integrate the uncertainty associated with imputation in the final parameter estimates.
Model estimation
The model will be estimated in the derivation cohort using a Cox proportional hazards regression. The assumption of proportional hazards will be checked visually by examining plots of Schoenfeld residuals versus time, and statistically by adding time-interacted predictors to the model. If the assumption is violated, then the investigators will consider the addition of time-interacted predictors to the model.
Considering the high ratio of expected events to degrees of freedom and the avoidance of data-driven variable selection, the risk of overfitting is judged to be low. However, this will be assessed statistically using the heuristic shrinkage estimator [(likelihood ratio Chi-square of the model - degree of freedom of the model)/likelihood ratio Chi-square of the model]. If this is <0.90, then the model will require adjustment for overfitting (e.g., by pursuing a variable reduction method or by applying shrinkage coefficients to the parameter estimates). Overfitting will also be assessed visually using the calibration curve.
Since the intention is to apply our model as a manual web-based calculator that could be used by healthcare providers, caregivers, and patients, the investigators will estimate a reduced model that seeks to optimize parsimony without a significant decrease in model performance. Indeed, the initial model may be too complex, labour-intensive, and time-consuming to be implemented. The reduced model will be estimated using the stepdown method, whereby sequentially, the variable with the lowest Wald Chi-square will be removed from the model until a minimally acceptable model performance is achieved. The reduced model will be compared to the initial model using Akaike's Information Criterion and measures of discrimination and calibration. The investigators will consider least absolute shrinkage and selection operator (LASSO), since it could result in the shrinkage of some regression coefficients to 0, thereby reducing the model. In addition to statistical means of model reduction, the investigators will consider the clinical relevance of the variable based existing literature and content expertise, in addition to the ability of patients and their caregivers to assess and input the variable.
The model will be developed and validated using temporally split samples; however, the final regression coefficients will be based on the full sample. The final model will have the same specifications as the derivation model.
Model performance
The model's performance will be assessed in the validation cohort in multiple domains. Specifically, it will be assessed in terms of overall performance, as measured by Nagelkerke's R2, which is a measure of the proportion of variability in the outcome that is explained by the model. Historically, clinical prediction tools have had R2 that ranged from 0.2 to 0.3. The model will also be assessed in terms of discrimination, as measured by the concordance (c) statistic and visualized by the receiver operating characteristic curve. The c statistic ranges from 0.5, which represents no discriminative ability, to 1.0, which represents perfect discriminative ability.
Finally, the model will be assessed in terms of calibration. This will be evaluated visually using the calibration curve of predicted versus observed mortality based on Kaplan Meier estimates at the abovementioned pre-specified survival times (3, 6, and 12 months). A perfectly calibrated model is represented by a 45-degree line with an intercept of 0 and a slope of 1. The calibration curve informs whether the model systematically over- or underestimates mortality risk (mean calibration or calibration-in-the-large) and whether it provides extreme predictions of mortality risk (i.e., underestimates risk in low-risk individuals and overestimates risk in high-risk individuals), which suggests overfitting. The mean relative difference between observed and predicted mortality risk will be calculated. An acceptable difference is <20% when the event rate is <=5%. Finally, to enable comparison to other prognostic models in community-dwelling individuals with dementia, the investigators will calculate the Integrated Calibration Index, the mean absolute difference between observed and predicted mortality risk; E50, the median absolute difference; and E90, the 90th percentile of absolute difference. Goodness-of-fit will not be measured by the Hosmer-Lemeshow statistic or its equivalent in a Cox proportional hazards model; these tests cannot provide a magnitude of miscalibration or determine whether miscalibration is present in only specific ranges of predicted mortality risk.
Calibration will also be assessed in decile groups based on predicted mortality risk (moderate calibration). Finally, subgroups of meaning to clinicians and policymakers will be pre-specified (e.g., defined by age, sex, comorbidities), in which calibration will be assessed. A calibration graph will be visualized and a mean relative difference will be calculated in each subgroup. Considering that individuals who underwent their randomly selected assessment in the hospital may be systematically different than those who underwent their assessment in the community, the investigators will specifically assess the model's performance in individuals who underwent an in-hospital assessment.
Model presentation
The final regression model, based on the total sample, will be presented using hazard ratios and associated 95% confidence intervals. The regression formula will be published online and be the basis for web-based implementation. Specifically, the model will be converted into a publicly accessible web-based manual calculator on www.projectbiglife.com, which houses multiple clinical prediction tools developed by our team. The tool could be used not only by healthcare providers, but also by patients and caregivers, to calculate life expectancy. Considering this, a team of web developers, web designers, implementation scientists, patients and caregivers, and clinicians will inform implementation to make the tool user-friendly and to make its output interpretable. The model interface and output may differ depending on whether a clinician or a patient/caregiver is using the tool. The investigators will respect the uncertainty associated with the output of the tool, by including interquartile ranges that transparently reflect prognostic uncertainty.
- Being tested
- There is no intervention. Exposures are predictor variables of mortality.
- Keywords
- Predictive Medicine
- Medical subject headings
- Dementia, Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
There is no intervention. Exposures are predictor variables of mortality.Other
Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
| Study group | Role | What they receive |
|---|---|---|
| Derivation | Individuals whose randomly selected assessment was done between April 1, 2010 and March 31, 2018, in whom model will be developed Receives: Other: There is no intervention. Exposures are predictor variables of mortality. | |
| Validation | Individuals whose randomly selected assessment was done between April 1, 2018 and March 31, 2020, in whom model's performance will be assessed Receives: Other: There is no intervention. Exposures are predictor variables of mortality. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Operationalized as time-to-event outcome
Measured: Maximum follow-up date is December 31, 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2024
- Study start1 Apr 2010
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 202,217 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- Sunnybrook Research Institute, Ottawa Hospital Research Institute, ICES
- Responsible party
- Principal investigator, Michael Bonares, University of Toronto
- Investigators
- Michael J Bonares, MD, MSc, Principal investigator, University of Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06266325
- Sponsor's protocol ID
- 6138
- Status last verified
- Mar 2024
- First submitted
- 9 Feb 2024
- Last updated
- 4 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Bonares M, Fisher S, Clarke A, Dover K, Quinn K, Stall N, Isenberg S, Tanuseputro P, Li W. Development and validation of a clinical prediction tool to estimate survival in community-dwelling adults living with dementia: a protocol. BMJ Open. 2024 Nov 17;14(11):e086231. doi: 10.1136/bmjopen-2024-086231.
PubMed 39551579
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of a Clinical Prediction Tool to Estimate Life Expectancy in Community-dwelling Individuals With Dementia
- ClinicalTrials.gov ID
- NCT06266325
- Acronym / sponsor ID
- 6138
- Keywords
- Predictive Medicine
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 202,217 participants (actual)
- Lead sponsor
- University of TorontoUniversity, hospital or other
- Collaborators
- Sunnybrook Research Institute, Ottawa Hospital Research Institute, ICES
- Study start
- 1 Apr 2010 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 20 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Individuals with dementia and their caregivers are faced with challenging decisions throughout the course of the disease. These decisions may be about medical care (e.g., continuation of routine cancer screening, pursuit of cardiopulmonary resuscitation, initiation of palliative care services), institutionalization (i.e., transition to a long-term care facility), or financial planning. These inherently difficult decisions are made more difficult by prognostic uncertainty. Indeed, life expectancy is challenging to predict in dementia. Consequently, prognosis is infrequently discussed by healthcare providers with individuals with dementia and their families, which compromises their ability to plan for the future. A lack of prognostic awareness makes it difficult for patients, their caregivers, and their healthcare providers to make medical decisions that strike the appropriate balance between prolonging life and promoting the quality of it. A clinical prediction tool has the promise to provide personalized and accurate estimations of life expectancy in individuals with dementia. Therefore, similar to the existing clinical prediction tools on our Project Big Life platform (www.projectbiglife.ca), we seek to create and to test a statistical model to predict survival, and to implement the model as a user-friendly, web-based calculator. The calculator will use self-reported sociodemographic, clinical, cognitive, functional, and nutritional information that is entered by patients, their caregivers, and/or their healthcare providers to output an estimated life expectancy. This estimate could inform the shared decision-making process, thereby empowering decisions that are compatible with a patient's clinical reality and concordant with their life goals.
Detailed description
Analysis plan
The analysis plan was informed by guidelines for clinical prediction modelling. The plan was developed after accessing the derivation dataset but before assessing predictor-outcome associations and model fitting. Key considerations are full pre-specification of the model, including selection of predictors, such that data-driven variable selection will be avoided. This will decrease the risk of bias and overfitting in the model. Second, continuous variables will be specified as restricted cubic splines with knots at fixed quantiles, such that categorization of continuous variables will be avoided. This will respect the non-linear nature of continuous variables, and will avoid the inefficiency and bias associated with categorization. Third, emphasis will be placed on the assessment of the model's calibration, not only in the validation cohort but also in subgroups of meaning to clinicians and policymakers. Statistical analysis will be performed using SAS Enterprise Guide V.9.4.
Validation will be performed using temporal validation, whereby the model's performance will be evaluated in a temporally distinct (more recent) cohort of individuals with dementia. This is a more rigorous form of validation compared to internal validation, which includes random splitting or resampling (bootstrapping, cross-validation). Whereas temporal validation evaluates transportability, internal validation evaluates only reproducibility. The size of the derivation cohort and the expected number of events therein enables temporal validation without significantly increasing the risk of overfitting.
Predictor variables
The candidate predictor variables were fully pre-specified, such that data-driven variable selection was avoided. The investigators reviewed variables in the home care databases to identify predictors. In addition, existing reviews of prognostic models in dementia were explored. Variables were reviewed by the research team in an itemized way to determine which to include in the initial model.
Notably, predictor values from only a single randomly selected assessment after dementia diagnosis (index assessment) will be included in the model. The investigators did not include values from subsequent assessments since the tool would be applied cross-sectionally, not longitudinally. Indeed, the team wants to avoid using values from subsequent assessments, which would not have been known at the time of the randomly selected assessment. The variables in our model will be organized in the following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information. The investigators will include interactions between age and variables that represent comorbidities since the association of these and life expectancy may vary with age. A linear term of age, not a restricted cubic spline thereof, will be used in interactions.
Outcome variable
The outcome variable will be survival time from the index assessment up to the maximum follow-up date (December 31st, 2022). Mortality will be discerned from the Registered Persons Database, which houses a historical listing of all individuals eligible for the Ontario Health Insurance Program, including sociodemographic (e.g., age, sex, postal code) and vital information (e.g., date of death). The investigators have pre-specified survival times of interest, which are compatible with current eligibility guidelines for specialist palliative care services (i.e., 3, 6, and 12 months).
Model specification
Predictor variables will be explored before assessing predictor-outcome associations or model fitting. Continuous variables will be explored using descriptive statistics and boxplots, and categorical variables using descriptive statistics and frequency distributions. Any identified invalid values will be corrected, if possible, or set to missing otherwise. Continuous variables will be specified using restricted cubic splines with knots at fixed quantiles (e.g., in a 5-knot spline, quantiles are placed at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles). Categorization of continuous variables will be avoided since this is associated with inefficiency and bias and does not respect the non-linear nature of continuous variables. Combination of levels of a categorical variable will be avoided unless a category has a very low proportion of total observations. Variables with a high degree of missing values or insufficient variation will be excluded. Multi-collinearity will be evaluated using variable clustering (VARCLUS function in SAS). The minimum proportion of variance explained by a cluster (eigenvalue) will be set to 0.7.
Missing values will be imputed using multiple imputation so long as missingness was judged to have been completely at random or at random. Despite its simplicity, complete case analysis will be avoided to prevent the inefficiency and bias associated with this method. The imputation model will include the outcome variable, predictor variables, and auxiliary variables (i.e., variables that are not included in the full model but that could inform the missing value of a variable). The number of imputed datasets will be based on the proportion of missing values in the dataset. The final model will be estimated in each of the imputed datasets. The parameter estimates based on each dataset will be combined using Rubin's rules, which integrate the uncertainty associated with imputation in the final parameter estimates.
Model estimation
The model will be estimated in the derivation cohort using a Cox proportional hazards regression. The assumption of proportional hazards will be checked visually by examining plots of Schoenfeld residuals versus time, and statistically by adding time-interacted predictors to the model. If the assumption is violated, then the investigators will consider the addition of time-interacted predictors to the model.
Considering the high ratio of expected events to degrees of freedom and the avoidance of data-driven variable selection, the risk of overfitting is judged to be low. However, this will be assessed statistically using the heuristic shrinkage estimator [(likelihood ratio Chi-square of the model - degree of freedom of the model)/likelihood ratio Chi-square of the model]. If this is <0.90, then the model will require adjustment for overfitting (e.g., by pursuing a variable reduction method or by applying shrinkage coefficients to the parameter estimates). Overfitting will also be assessed visually using the calibration curve.
Since the intention is to apply our model as a manual web-based calculator that could be used by healthcare providers, caregivers, and patients, the investigators will estimate a reduced model that seeks to optimize parsimony without a significant decrease in model performance. Indeed, the initial model may be too complex, labour-intensive, and time-consuming to be implemented. The reduced model will be estimated using the stepdown method, whereby sequentially, the variable with the lowest Wald Chi-square will be removed from the model until a minimally acceptable model performance is achieved. The reduced model will be compared to the initial model using Akaike's Information Criterion and measures of discrimination and calibration. The investigators will consider least absolute shrinkage and selection operator (LASSO), since it could result in the shrinkage of some regression coefficients to 0, thereby reducing the model. In addition to statistical means of model reduction, the investigators will consider the clinical relevance of the variable based existing literature and content expertise, in addition to the ability of patients and their caregivers to assess and input the variable.
The model will be developed and validated using temporally split samples; however, the final regression coefficients will be based on the full sample. The final model will have the same specifications as the derivation model.
Model performance
The model's performance will be assessed in the validation cohort in multiple domains. Specifically, it will be assessed in terms of overall performance, as measured by Nagelkerke's R2, which is a measure of the proportion of variability in the outcome that is explained by the model. Historically, clinical prediction tools have had R2 that ranged from 0.2 to 0.3. The model will also be assessed in terms of discrimination, as measured by the concordance (c) statistic and visualized by the receiver operating characteristic curve. The c statistic ranges from 0.5, which represents no discriminative ability, to 1.0, which represents perfect discriminative ability.
Finally, the model will be assessed in terms of calibration. This will be evaluated visually using the calibration curve of predicted versus observed mortality based on Kaplan Meier estimates at the abovementioned pre-specified survival times (3, 6, and 12 months). A perfectly calibrated model is represented by a 45-degree line with an intercept of 0 and a slope of 1. The calibration curve informs whether the model systematically over- or underestimates mortality risk (mean calibration or calibration-in-the-large) and whether it provides extreme predictions of mortality risk (i.e., underestimates risk in low-risk individuals and overestimates risk in high-risk individuals), which suggests overfitting. The mean relative difference between observed and predicted mortality risk will be calculated. An acceptable difference is <20% when the event rate is <=5%. Finally, to enable comparison to other prognostic models in community-dwelling individuals with dementia, the investigators will calculate the Integrated Calibration Index, the mean absolute difference between observed and predicted mortality risk; E50, the median absolute difference; and E90, the 90th percentile of absolute difference. Goodness-of-fit will not be measured by the Hosmer-Lemeshow statistic or its equivalent in a Cox proportional hazards model; these tests cannot provide a magnitude of miscalibration or determine whether miscalibration is present in only specific ranges of predicted mortality risk.
Calibration will also be assessed in decile groups based on predicted mortality risk (moderate calibration). Finally, subgroups of meaning to clinicians and policymakers will be pre-specified (e.g., defined by age, sex, comorbidities), in which calibration will be assessed. A calibration graph will be visualized and a mean relative difference will be calculated in each subgroup. Considering that individuals who underwent their randomly selected assessment in the hospital may be systematically different than those who underwent their assessment in the community, the investigators will specifically assess the model's performance in individuals who underwent an in-hospital assessment.
Model presentation
The final regression model, based on the total sample, will be presented using hazard ratios and associated 95% confidence intervals. The regression formula will be published online and be the basis for web-based implementation. Specifically, the model will be converted into a publicly accessible web-based manual calculator on www.projectbiglife.com, which houses multiple clinical prediction tools developed by our team. The tool could be used not only by healthcare providers, but also by patients and caregivers, to calculate life expectancy. Considering this, a team of web developers, web designers, implementation scientists, patients and caregivers, and clinicians will inform implementation to make the tool user-friendly and to make its output interpretable. The model interface and output may differ depending on whether a clinician or a patient/caregiver is using the tool. The investigators will respect the uncertainty associated with the output of the tool, by including interquartile ranges that transparently reflect prognostic uncertainty.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Derivation | – | Other: There is no intervention. Exposures are predictor variables of mortality.Individuals whose randomly selected assessment was done between April 1, 2010 and March 31, 2018, in whom model will be developed |
| Validation | – | Other: There is no intervention. Exposures are predictor variables of mortality.Individuals whose randomly selected assessment was done between April 1, 2018 and March 31, 2020, in whom model's performance will be assessed |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- The cohort will comprise individuals with dementia who are expected to be or currently are recipients of long-stay home care, who, after diagnosis of dementia, underwent any home care assessment from April 1st, 2010 to March 31st, 2020
Key inclusion criteria (2 listed)
- Diagnosed with dementia determined by a combination of a validated case definition and by indicators of dementia in the home care assessment
- Recipients of home care, who, after diagnosis of dementia, underwent any home care assessment from April 1st, 2010 to March 31st, 2020
Key exclusion criteria (4 listed)
- Age <65 on the date of dementia diagnosis
- Invalid age or sex
- Invalid birthdate (e.g., after date of dementia diagnosis) or death date (e.g., before date of dementia diagnosis)
- Ineligibility for Ontario Health Insurance Program at the time of the home care assessment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| There is no intervention. Exposures are predictor variables of mortality.Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information. | Other | Derivation, Validation |
Primary outcome
Mortality
Time frame: Maximum follow-up date is December 31, 2022
Operationalized as time-to-event outcome
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2024.
- Derived from this study: PubMed 39551579Bonares M, Fisher S, Clarke A, Dover K, Quinn K, Stall N, Isenberg S, Tanuseputro P, Li W. Development and validation of a clinical prediction tool to estimate survival in community-dwelling adults living with dementia: a protocol. BMJ Open. 2024 Nov 17;14(11):e086231. doi: 10.1136/bmjopen-2024-086231.
- Individual participant dataSharing planned: No
Related trials for Dementia
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
Active, not recruiting
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Dementia, Cognitive Impairment
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Amnesia, Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael J Bonares, MD, MSc principal investigator
University of Toronto
Questions about this trial
What is this clinical trial studying?
An observational study of Dementia and Death, run by University of Toronto.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: Maximum follow-up date is December 31, 2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06266325, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2024.